CMO Loretta Itri resigns; Executive Chairman Neil Desai steps down on Oct 1, 2024

Whitehawk Therapeutics, Inc.

CMO Dr. Loretta Itri voluntarily resigns effective Oct 1, 2024; receives 12 months severance pay plus COBRA reimbursement.
Executive Chairman Neil Desai terminated effective Oct 1, 2024; receives severance per agreement; remains on board.
Dr. Itri enters consulting arrangement: 10 hrs/month, $8,000 monthly retainer, initial 3-month term.
Both executives continue vesting in equity awards during consulting/board service.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Loretta Itri

Chief Medical Officer

WHWK · Whitehawk Therapeutics, Inc.

Effective: 2024-10-01
Filed: August 22, 2024, 7:59 PM ET

On August 16, 2024, Loretta Itri, M.D. notified the board of directors of the Company (the “Board”) that her employment as Chief Medical Officer will cease effective October 1, 2024.

Departed

Neil Desai

Executive Chairman

WHWK · Whitehawk Therapeutics, Inc.

Effective: 2024-10-01
Filed: August 22, 2024, 7:59 PM ET

On August 20, 2024, Neil Desai, Ph.D, was notified that his employment as Executive Chairman of the Company will cease on October 1, 2024.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Loretta Itri resigned as Chief Medical Officer at Whitehawk Therapeutics, Inc..

Action: resigned
Role: Chief Medical Officer

Exact text from the filing

On August 16, 2024, Loretta Itri, M.D. notified the board of directors of the Company (the “Board”) that her employment as Chief Medical Officer will cease effective October 1, 2024.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.9

Neil Desai was terminated as Executive Chairman at Whitehawk Therapeutics, Inc..

Action: terminated
Role: Executive Chairman

Exact text from the filing

On August 20, 2024, Neil Desai, Ph.D, was notified that his employment as Executive Chairman of the Company will cease on October 1, 2024.

View on SEC.gov

Whitehawk Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-205370

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.